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Summary
Background.  —  Recent  clinical  studies  suggest  that  low-molecular-weight  heparin  (LMWH)  could
be an  effective  and  safe  alternative  to  unfractionated  heparin  (UFH)  for  patients  with  acute
myocardial  infarction  (AMI).
Aims.  —  To  assess  the  impact  of  anticoagulant  choice  (LMWV  vs  UFH)  on  bleeding,  the  need  for
blood transfusion  and  3-year  clinical  outcomes  in  AMI  patients  from  the  FAST-MI  registry.
Methods.  —  FAST-MI  was  a  nationwide  registry  compiled  in  France  over  1  month  in  2005,  which
included consecutive  AMI  patients  admitted  to  an  intensive  care  unit  less  than  48  hours  from
symptom onset  in  223  participating  centres.
Results.  —  A  total  of  2854  patients  treated  with  heparins  were  included.  The  risks  of  major
bleeding or  transfusion  (3.0%  vs  7.0%)  and  in-hospital  death  (3.2%  vs  9.2%)  were  lower  with  LMWH
compared  with  UFH,  a  difference  that  persisted  after  multivariable  adjustment  (odds  ratio  [OR]
0.51, 95%  conﬁdence  interval  [CI]  0.34—0.76  and  OR  0.53,  95%  CI  0.37—0.76,  respectively).
Three-year  survival,  and  stroke  and  reinfarction-free  survival  risks  were  also  higher  with  LMWH
compared  with  UFH  (adjusted  hazard  ratio  [HR]  0.73,  95%  CI  0.61—0.87  and  HR  0.73,  95%  CI
0.62—0.85, respectively).  In  two  cohorts  of  patients  matched  on  propensity  score  for  receiving
LMWH and  with  similar  baseline  characteristics  (834  patients  per  group),  major  bleeding  and
transfusion  rates  were  lower  while  the  3-year  survival  rate  was  signiﬁcantly  higher  in  patients
receiving  LMWH.
Conclusion.  —  Our  data  suggest  that  the  use  of  LMWH  in  AMI  patients  may  have  a  better  bene-
ﬁt/risk proﬁle  than  UFH,  in  terms  of  bleeding,  need  for  transfusion  and  long-term  survival.
© 2012  Published  by  Elsevier  Masson  SAS.
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Résumé
Contexte.  —  Les  dernières  études  cliniques  suggèrent  que  les  héparines  de  bas  poids  molécu-
laires (HBPM)  représentent  une  alternative  sûre  et  efﬁcace  à  l’héparine  non  fractionnée  (HNF)
pour la  prise  en  charge  des  patients  avec  un  infarctus  du  myocarde  (IDM).
Objectifs.  —  Évaluer  l’impact  des  HBPM  par  rapport  à  l’HNF  sur  les  saignements  et  le  devenir
des patients  présentant  un  IDM  à  partir  du  registre  FAST-MI.
Méthodes.  —  FAST-MI  est  un  registre  national  ayant  inclus  au  cours  d’un  mois  ﬁn  2005  les  patients
ayant présenté  un  IDM  au  sein  de  223  centres  participants.  Nous  avons  évalué  l’impact  des  HBPM
sur les  saignements,  les  transfusions  et  la  survie  à  trois  ans.
Résultats.  — Au  total,  2854  patients  traités  par  héparine  ont  été  inclus.  Le  risque  de  saigne-
ment majeur  ou  de  transfusion  (3,0  %  vs  7,0  %,  p  <  0,001)  et  de  décès  intra-hospitalier  (3,2  %
vs 9,2  %,  p  <  0,001)  étaient  signiﬁcativement  moins  élevés  avec  les  HBPM  qu’avec  l’HNF  ;  résul-
tats conﬁrmés  sur  les  analyses  multivariées  (OR  0,51,  IC  95  %  0,34—0,76  et  OR  0,53,  IC  95  %
0,37—0,76,  respectivement).  L’utilisation  des  HBPM  était  associée  de  fac¸on  signiﬁcative  à
une meilleur  survie  à  trois  ans  et  à  la  survenue  de  moins  d’événements  cardiovasculaires
majeurs (décès,  infarctus,  accident  vasculaire  cérébral)  comparée  à  l’HNF  (HR  0,73,  IC  95  %
0,61—0,87 et  HR  0,73,  IC  95  %  0,62—0,85,  respectivement).  Sur  deux  cohortes  de  patients
appariés avec  un  score  de  propensité  (834  patients  par  groupe),  les  patients  traités  par  HBPM
avaient signiﬁcativement  une  meilleure  survie  à  trois  ans  et  moins  de  saignements  majeurs  et
de transfusions.
Conclusion.  —  Cette  étude  démontre  que  l’utilisation  des  HBPM  chez  les  patients  présentant  un
IDM est  associée  à  une  diminution  des  saignements,  des  transfusions  et  à  une  meilleure  survie
comparée à  ceux  traités  par  HNF.
© 2012  Publié  par  Elsevier  Masson  SAS.
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everal  clinical  studies  have  demonstrated  that  LMWHs
mainly  enoxaparin)  are  an  effective  and  safe  alternative  to
FH  for  the  management  of  patients  with  ACS,  with  clinical
eneﬁt  maintained  long-term  [1—8]. A  recent  meta-analysis
ncluding  more  than  30,000  patients  undergoing  PCI  showed
hat  enoxaparin  is  superior  to  UFH  in  reducing  mortality  and
leeding  outcomes,  especially  in  patients  undergoing  PCI  for
i
e
fTEMI  [9].  This  meta-analysis  conﬁrms  the  results  recently
eported  in  the  ATOLL  randomized  trial,  in  which  the  use  of
ntravenous  enoxaparin  compared  with  UFH  reduced  clini-
al  ischaemic  outcomes  without  differences  in  bleeding  and
rocedural  success  [10].We  aimed  to  determine,  in  a  ‘‘real-world’’  setting,  the
mpact  of  LMWH  compared  with  UFH,  in  terms  of  bleeding
vents  and  long-term  clinical  outcomes  in  patients  with  AMI
rom  the  FAST-MI.
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Methods
Patient population
The  methods  of  the  FAST-MI  registry  have  been  described
in  detail  elsewhere  [11,12].  Brieﬂy,  the  primary  objective
was  to  evaluate  ‘‘real-life’’  MI  management  practices  and
to  measure  their  impact  on  medium-  and  long-term  progno-
sis  in  patients  admitted  to  ICUs  with  AMI  (within  48  hours).
This  registry  resulted  from  a  prospective  multicentre  (223
centres)  study  that  included  3059  patients.  Patients  were
recruited  consecutively  from  ICUs  over  a  period  of  1  month
(October  2005).  Participation  in  the  study  was  offered  to
all  French  institutions,  university  teaching  hospitals,  general
and  regional  hospitals  and  private  clinics  with  ICUs  capable
of  receiving  ACS  emergencies.
Men  and  women  aged  over  18  years  were  included  if  they
agreed  to  take  part  in  the  study  and  were  admitted  within
48  hours  after  symptom  onset  for  an  AMI  characterized  by
the  elevation  of  troponin  or  creatine  phosphokinase-MB
associated  with  at  least  one  of  the  following  elements:
symptoms  compatible  with  myocardial  ischaemia;  new
pathological  Q  waves;  and  ST-T  changes  compatible  with
myocardial  ischaemia.
Main  exclusion  criteria  were:  iatrogenic  MI  (deﬁned  as
an  MI  occurring  within  48  hours  of  a  therapeutic  proce-
dure  [bypass  surgery,  coronary  angioplasty  or  any  other
medical  or  surgical  intervention]);  ACS  diagnosis  invalidated
in  favour  of  another  diagnosis;  unstable  angina;  and  no
increase  in  cardiac  biomarkers.
Participation  in  the  registry  did  not  change  the  thera-
peutic  approach  of  the  cardiologist  in  any  way.  The  registry
was  conducted  in  compliance  with  Good  Clinical  Practice,
French  Law  and  the  French  Data  Protection  Law.  The  pro-
tocol  was  reviewed  by  the  Committee  for  the  Protection
of  Human  Subjects  in  Biomedical  Research  of  Saint-Antoine
Hospital  and  the  FAST-MI  registry  data  ﬁle  was  declared  to
the  Commission  Nationale  Informatique  et  Liberté.  Clinical-
trials.gov  identiﬁer:  NCT00673036.
Deﬁnition of the heparin groups
Two  groups  were  formed  according  to  the  anticoagulant  used
during  the  ﬁrst  48  hours:  the  LMWH  group  and  the  UFH  group.
Patients  who  received  both  anticoagulants  were  included  in
the  LMWH  group.
Deﬁnition of myocardial infarction and
strategy
Although  the  diagnosis  of  AMI  was  independently  made  at
each  participating  centre,  to  avoid  heterogeneous  criteria
it  was  suggested  that  STEMI  be  deﬁned  as  ST-segment  ele-
vation  more  than  or  equal  to  1  mm  or  new  bundle  branch
block  seen  in  at  least  two  contiguous  leads  at  any  loca-
tion  in  the  index  or  qualifying  electrocardiogram,  and  that
NSTEMI  (non-Q  wave  MI)  be  deﬁned  as  no  ST-segment  ele-
vation  seen  in  the  index  or  qualifying  electrocardiogram.
Patients  who  died  very  early  after  admission  and  in  whom
cardiac  markers  were  not  measured  were  included  if  they
had  compatible  signs  or  symptoms  associated  with  typical  ST
changes.
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ata collection and follow-up
ata  on  baseline  characteristics  (demographics,  risk  fac-
ors  and  medical  history)  were  collected  prospectively.  All
ata  were  recorded  on  computerized  case  record  forms  by
edicated  research  technicians  sent  to  each  of  the  cen-
res  at  least  once  a  week.  Follow-up  data  were  collected
hrough  contact  with  the  attending  physicians,  the  patients
r  their  families.  If  missing,  vital  status  was  assessed  from
he  registry  of  the  patient’s  birthplace.  Three-year  follow-
p  was  97%  complete.  Bleeding  was  classiﬁed  as  major  or
inor  according  to  the  TIMI  criteria  [13]. Regarding  bleed-
ng  complications,  four  endpoints  of  interest  were  used:
n-hospital  major  bleeding  (deﬁned  as  a  fall  in  haemoglobin
ore  than  or  equal  to  5  g,  a  fall  in  haematocrit  more  than
r  equal  to  15%,  intracranial  haemorrhage,  retroperitoneal
leeding);  minor  bleeding  (deﬁned  as  fall  in  haemoglobin
f  3—5  g/dL,  a  fall  in  haematocrit  of  10—15%);  use  of  any
ransfusion  during  the  hospital  stay;  and  3-year  survival.
tatistical analysis
tatistical  analysis  was  performed  using  SPSS  20.0  software
IBM,  Armonk,  NY,  USA).  For  quantitative  variables,  means,
tandard  deviations  and  minimum  and  maximum  values  were
alculated.  In  addition,  medians  with  interquartile  ranges
ere  calculated  for  some  of  the  variables.  Discrete  varia-
les  are  presented  as  percentages.  Comparisons  were  made
ith  the  Chi2 test  or  Fisher’s  exact  test  for  discrete  variables
nd  with  unpaired  t  tests,  Wilcoxon  sign-rank  tests  or  one-
ay  analyses  of  variance  for  continuous  variables.  Survival
urves  according  to  management  methods  were  estimated
sing  the  Kaplan—Meier  estimation  and  compared  using  a
og-rank  test.  Multivariable  analyses  of  predictors  of  in-
ospital  endpoints  were  made  by  using  a  backward  stepwise
ultiple  logistic  regression  method.  Correlates  of  survival
ere  determined  using  a  multivariable  backward  stepwise
ox  analysis.  Variables  listed  in  Table  1  were  included  in
he  models.  In  addition,  a  propensity  score  for  receiving
MWH  was  calculated  using  multiple  logistic  regression  and
as  used  to  build  two  cohorts  of  patients  matched  on  the
ropensity  score.  Comparisons  of  events  between  the  two
ropensity  score-matched  cohorts  were  made  using  simi-
ar  methodology.  For  all  analyses,  P  <  0.05  was  considered
igniﬁcant.
esults
f  the  3059  patients  included  in  the  registry,  2854  received
eparin  (either  UFH  or  LMWH)  during  the  ﬁrst  48  hours;  6.7%
f  patients  did  not  receive  any  heparin  for  various  reasons
nd  were  excluded  from  the  analysis.
aseline characteristics
aseline  characteristics  are  described  in  Table  1;  1932
atients  (67%)  received  LMWH  and  922  patients  received
FH  during  the  ﬁrst  48  hours.  Patients  who  received  UFH
ere  older  and  had  a  higher  cardiovascular  risk  (with  a
igher  GRACE  score)  and  a  lower  left  ventricular  ejection
raction  than  those  who  received  LMWH.
350  É.  Puymirat  et  al.
Table  1  Baseline  characteristics:  demographics,  risk  factors  and  clinical  variables  on  admission.
UFH  (n  =  922)  LMWH  (n  =  1932)  P
Age  (years) 68.9  ±  14.4  65.5  ±  14.2  <0.001
Women  310  (34)  590  (31)  0.05
Body  mass  index  (kg/m2)  26.9  ±  5.0  26.9  ±  4.5  0.98
Hypertension  561  (61)  1055  (55)  0.001
Diabetes  mellitus 231  (25)  424  (22)  0.04
Current  smoking 273  (30) 600  (31) 0.23
Hyperlipidaemiaa 414  (45) 940  (49) 0.03
Previous  MI 160  (17) 318  (17) 0.29
Previous  percutaneous  intervention  114  (12)  253  (13)  0.32
Previous  coronary  artery  bypass  grafting  61  (7)  86  (5)  0.01
Previous  heart  failure  62  (7)  84  (4)  0.005
Previous  stroke  55  (6)  83  (4)  0.03
Peripheral  artery  disease  105  (11)  149  (8)  0.001
Chronic  renal  insufﬁciency  81  (9)  62  (3)  <0.001
STEMI  551  (60)  970  (50)  <0.001
GRACE  score  158  ±  38  143  ±  35  <0.001
Left  ventricular  ejection  fraction  (%)  45  ±  14  53  ±  13  <0.001
Atrial  ﬁbrillation  on  admission  91  (10)  118  (6)  <0.001
Admission  glycaemia  (mg/dL)  158  ±  78  146  ±  65  <0.001
Admission  creatinine  (mg/dL)  117  ±  87  92  ±  30  <0.001
Left  bundle  branch  block  on  admission  46  (5)  63  (3)  0.02
Anterior  MI  (%  of  STEMI)  235  (43)  366  (38)  0.03
Fibrinolytic  treatment  196  (21)  265  (14)  <0.001
Admission  Killip  class  ≥  2  253  (28)  365  (19)  <0.001
Antiplatelet  agents  before  225  (25)  470  (24)  0.50
Beta-blockers  before  219  (24)  447  (23)  0.38
Statins  before  233  (25)  515  (27)  0.23
Angiotensin-converting  enzyme  inhibitors  before  318  (35)  609  (32)  0.06
Diuretics  before  262  (28)  432  (22)  <0.001
Calcium  channel  blockers  before  189  (21)  333  (17)  0.02
Data are mean ± standard deviation or number (%). GRACE: global registry of acute coronary events; LMWH: low-molecular-weight
heparin; MI: myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial
infarction; UFH: unfractionated heparin.
a Included patients with previously documented diagnosis of hypercholesterolaemia treated with diet or medication, or new diagnosis
made during this hospitalization with elevated total cholesterol more than 160 mg/dL; did not include elevated triglycerides.
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n-hospital  complications  are  described  in  Table  2.  Major
leeding  and  blood  transfusions  occurred  less  frequently
ith  LMWH  compared  with  UFH.  Speciﬁcally,  however,
ntracranial  haemorrhage  (UFH  0.2%  vs  LMWH  0.1%),
etroperitoneal  bleeding  (0.8%  vs  0.3%)  and  minor  bleeding
1.6%  vs  0.8%)  were  not  different.  A  signiﬁcant  interac-
ion  regarding  the  risk  of  major  bleeding  or  transfusion
as  noted  between  type  of  heparin  and  use  of  ﬁbrinolytic
reatment,  with  a  lower  risk  with  LMWH  in  patients  not
eceiving  ﬁbrinolytic  agents  (2.9%  vs  8.4%)  and  a higher
isk  in  those  treated  with  ﬁbrinolytics  (3.0%  vs  2.0%)  (P
or  interaction  =  0.02).  Rates  of  in-hospital  reinfarction  (UFH
.3%  vs  LMWH  1.9%)  and  stroke  (0.9%  vs  1.0%)  did  not  dif-
er  signiﬁcantly.  The  in-hospital  mortality  rate  was  higher
n  patients  receiving  UFH  (9.2%  vs  3.2%).  Among  the  1932
MWH-treated  patients,  837  (43%)  also  received  UFH  at  some
ime  during  the  ﬁrst  48  hours  following  admission  or  in  the
rehospital  setting.  The  rates  of  major  bleeding  and  blood
l
r
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rransfusions  were  similar  in  those  receiving  LMWH  compared
ith  those  receiving  both  types  of  heparins  (1.8%  vs  1.6%,
 =  0.65  and  3.1%  vs  2.4%,  P  =  0.34,  respectively).  Using  mul-
ivariable  logistic  regression  analysis,  the  use  of  LMWH  was
ssociated  with  a  lower  risk  of  major  bleeding  or  blood  trans-
usion  and  a  lower  risk  of  in-hospital  death  (odds  ratio  0.53,
5%  CI  0.37—0.76,  P <  0.001).  Other  independent  predictors
ere  chronic  kidney  failure  for  major  bleeding  and  periph-
ral  arterial  disease,  use  of  angiotensin  receptor  blockers
efore,  and  chronic  renal  failure  for  blood  transfusions.
ong-term clinical outcomes
ong-term  clinical  outcomes  are  described  in  Table  2.  The  3-
ear  survival  rate  was  higher  in  patients  treated  with  LMWH
ompared  with  UFH  (84.3%  vs  72.5%,  P  <  0.001)  (Fig.  1).  Simi-
arly,  the  risk  of  major  adverse  cardiac  events  (3-year  death,
einfarction  and  stroke)  was  also  lower  with  LMWH  (68.1%  vs
0%,  P  <  0.001)  (Fig.  2).  Subgroup  analyses  showed  consistent
esults  in  STEMI  or  NSTEMI,  men  or  women,  low  (less  than
LMWH  versus  UFH  in  acute  myocardial  infarction  351
Table  2  In-hospital  complications  and  3-year  clinical  outcomes.
UFH  (n  =  922)  LMWH  (n  =  1932)  Adjusted  OR  or  HR  (95%  CI)  P
Major  bleeding 32  (3.5)  33  (1.7)  0.66  (0.36—1.21)  0.17
Any  blood  transfusion  62  (6.7)  54  (2.8)  0.50  (0.33—0.75)  0.001
Major  bleeding  or  transfusion  65  (7.0)  57  (3.0)  0.51  (0.34—0.76)  <  0.001
Three-year  death  254  (27.5)  303  (15.7)  0.73  (0.61—0.86)  <  0.001
Three-year  death,  MI  or  stroke 294  (31.9)  387  (20.0)  0.73  (0.62—0.85)  <  0.001
Data are number (%). HR: hazard ratio; LMWH: low-molecular-weight heparin; MI: myocardial infarction; OR: odds ratio; UFH:
unfractionated heparin.
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mor  equal  to  23)  or  normal/high  body  mass  index,  use  of  PCI
or  not  and  increased  creatinine  concentration  (more  than
or  equal  to  150  mg/dL)  or  not.  Moreover,  the  3-year  survival
rate  was  similar  in  patients  who  received  only  LMWH  and  in
those  who  received  both  LMWH  and  UFH  (LMWH  only  84.6%  vs
combination  84.0%,  P  =  0.69).  Using  Cox  multivariable  anal-
ysis,  the  use  of  LMWH  was  associated  with  a  reduced  risk
of  death  at  3  years;  other  independent  predictors  were  the
GRACE  score,  the  presence  of  an  anterior  MI,  chronic  renal
failure  and  history  of  stroke.  Likewise,  the  risk  of  death,  re-
MI  or  stroke  at  3  years  was  signiﬁcantly  reduced  with  LMWH
therapy  (Table  2).  In  the  subgroup  of  patients  without  major
bleeding  or  transfusion,  the  use  of  LMWH  remained  associ-
ated  with  a  reduced  risk  of  3-year  death  (15.1%  vs  25.6%;
hazard  ratio  0.75,  95%  CI  0.62—0.90,  P  =  0.002)  and  of  3-
year  death,  re-MI  or  stroke  (19.6%  vs  30.1%;  hazard  ratio
0.75,  95%  CI  0.64—0.89,  P  =  0.001).Propensity score-matched cohorts
The  propensity  score  for  receiving  LMWH  vs  UFH  was  used  to
build  two  matched  cohorts  of  834  patients  each,  which  had
Figure 1. Three-year survival according to type of heparin used
(whole population). Log-rank: 2 = 62.18, P < 0.001. CI: conﬁdence
interval; HR: hazard ratio; LMWH: low-molecular-weight heparin;
UFH: unfractionated heparin.
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himilar  baseline  characteristics  (Table  3).  As  in  the  overall
opulation,  major  bleeding  and  use  of  transfusions  occurred
ess  frequently  in  LMWH-treated  patients.  Three-year  sur-
ival,  and  3-year  re-MI  and  stroke-free  survival  rates  were
igniﬁcantly  higher  in  the  patients  who  received  LMWH  com-
ared  with  those  who  did  not  (79%  vs  75%  and  75%  vs  71%,
espectively)  (Figs.  3  and  4).
iscussion
he  present  data,  gathered  from  a  nationwide  registry  of
atients  admitted  for  AMI,  suggest  a  better  beneﬁt/risk  in
atients  using  LMWH  compared  with  UFH  at  the  acute  stage
f  MI,  with  a  reduced  risk  of  bleeding  and  improved  3-
ear  survival.  This  favourable  proﬁle  was  consistent  across
atient  subgroups  and  persisted  after  multivariable  adjust-
ents  and  in  propensity  score-matched  cohorts.  The  results
xtend  our  previous  ﬁndings  in  elderly  patients  [14].
In  this  prospective  registry,  the  use  of  LMWH  was  asso-
iated  with  a  27%  relative  risk  reduction  in  mortality  after
igure 2. Three-year myocardial infarction and stroke-free
urvival (whole population). Log-rank: 2 = 56.03, P < 0.001. CI:
onﬁdence interval; HR: hazard ratio; LMWH: low-molecular-weight
eparin; UFH: unfractionated heparin.
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Table  3  Baseline  characteristics  in  cohorts  matched  on  propensity  score.
UFH  (n  =  834)  LMWH  (n  =  834)  P
Age  (years) 68.5  ±  14.6  68.6  ±  14.0  0.88
Women  276  (33)  277  (33)  0.50
Body  mass  index  (kg/m2)  26.9  ±  5.1  26.7  ±  4.6  0.54
Hypertension 495  (59)  510  (61)  0.24
Diabetes  mellitus 193  (23) 189  (23)  0.43
Current  smoking 254  (31) 253  (30) 0.50
Hyperlipidaemiaa 371  (45) 362  (43) 0.35
Previous  MI  138  (17)  144  (17)  0.37
Previous  percutaneous  intervention  102  (12)  104  (13)  0.47
Previous  coronary  artery  bypass  grafting  50  (6)  38  (5)  0.11
Previous  heart  failure  53  (6)  45  (5)  0.23
Previous  stroke  45  (5)  47  (6)  0.46
Peripheral  artery  disease  87  (10)  83  (10)  0.40
Chronic  renal  insufﬁciency  42  (5)  44  (5)  0.46
STEMI  505  (61)  516  (62)  0.85
GRACE  score  155  ±  37  155  ±  37  0.90
Fibrinolytic  treatment  179  (21.5)  166  (20)  0.43
Left  ventricular  ejection  fraction  (%)  50  ±  14  52  ±14  0.06
Atrial  ﬁbrillation  on  admission  78  (9)  74  (9)  0.40
Admission  Killip  class  ≥  2  211  (25)  211  (25)  0.52
Admission  glycaemia  (mg/dL)  157  ±  76  153  ±  66  0.23
Admission  creatinine  (mg/dL)  101  ±  41  101  ±  38  0.89
Left  bundle  branch  block  on  admission  38  (5)  39  (5)  0.50
Anterior  MI  (%  of  STEMI)  216  (43)  217  (42)  0.43
Use  of  thrombolysis  196  (21)  265  (14)  <0.001
Antiplatelet  agents  before  197  (24)  214  (26)  0.18
Beta-blockers  before  191  (23)  195  (22)  0.39
Statins  before  208  (25)  201  (24)  0.37
Angiotensin-converting  enzyme  inhibitors  before  271  (33)  302  (36)  0.06
Diuretics  before 221  (26)  238  (29)  0.19
Calcium  channel  blockers  before 163  (20) 158  (19)  0.40
Clopidogrel  in  ﬁrst  48  hours 690  (83)  690  (83)  0.53
Use  of  GP  IIb/IIIa  inhibitors 288  (35) 303  (36)  0.24
Data are mean ± standard deviation or number (%). GP: glycoprotein; GRACE: global registry of acute coronary events; LMWH: low-
molecular-weight heparin; MI: myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment
elevation myocardial infarction; UFH: unfractionated heparin.
a Included patients with previously documented diagnosis of hypercholesterolaemia treated with diet or medication, or new diagnosis
made during this hospitalization with elevated total cholesterol more than 160 mg/dL; did not include elevated triglycerides.
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c years  of  follow-up,  compared  with  UFH.  This  beneﬁt  was
bserved  regardless  of  type  of  ACS  (STEMI  or  NSTEMI),  sex,
ody  mass  index,  use  of  PCI  and  creatinine  concentration.
ur  results  are  consistent  with  current  published  data  and
specially  with  the  recent  meta-analysis  by  Silvain  et  al.,
n  which  the  use  of  enoxaparin  was  associated  with  a  34%
elative  risk  reduction  in  mortality  compared  with  UFH
1—9].  However,  subgroup  analyses  suggested  that  the  ben-
ﬁts  on  mortality  and  ischaemic  complications  were  largely
riven  by  the  drug  superiority  in  patients  undergoing  pri-
ary  PCI  for  STEMI,  whereas  the  better  safety  outcomes
ight  be  driven  by  the  intravenous  (vs  subcutaneous)  use
f  enoxaparin.  These  data  conﬁrm  results  recently  reported
n  the  ATOLL  randomized  trial  [10]. Compared  with  UFH,
ntravenous  enoxaparin  at  a  dose  of  0.5  mg/kg  in  patients
ndergoing  primary  PCI  reduced  death  or  resuscitated  car-
iac  death  in  patients  undergoing  primary  PCI  by  42%  and
b
o
o
teath  or  MI  by  37%.  Although  the  40%  relative  risk  reduction
n  all-cause  mortality  associated  with  enoxaparin  in  ATOLL
as  not  signiﬁcant  (P  =  0.08),  it  is  consistent  with  the  38%
eduction  in  mortality  found  in  the  group  with  STEMI  in  the
urrent  meta-analysis  (P  <  0.001).
This  survival  beneﬁt  is  supported  by  concomitant  reduc-
ions  in  both  ischaemic  and  major  bleeding  complications,
lthough  in  our  study  the  survival  beneﬁt  was  driven  by  a
eduction  in  bleeding  outcomes  only.  Similar  reductions  in
ortality  were  found  in  studies  with  only  a  reduction  in
leeding  outcomes,  and  support  our  ﬁndings  [15]. Regarding
leedings,  some  studies  have  shown  that  the  increased  efﬁ-
acy  of  LMWH  may  be  accompanied  by  an  increased  risk  of
leeding,  especially  in  high-risk  patients,  such  as  the  elderly
r  patients  with  renal  failure  who  may  receive  an  overdose
f  LMWH,  which  needs  to  be  adapted  in  this  fragile  popula-
ion  [16—18]. However,  this  is  disputed  by  most  data  from
LMWH  versus  UFH  in  acute  myocardial  infarction  
Figure 3. Three-year survival according to type of heparin used
(propensity score-matched groups). Log-rank: 2 = 4.58, P = 0.032.
p
t
C
e
g
i
a
l
H
p
e
m
S
O
—
b
r
i
o
b
a
o
o
a
o
o
i
E
tLMWH: low-molecular-weight heparin; UFH: unfractionated hep-
arin.
the  literature,  which  did  not  ﬁnd  a  signiﬁcantly  increased
risk  associated  with  the  use  of  LMWH,  although  an  increase  in
minor  bleeding  has  been  reported  [1,2,19—22].  In  our  study,
the  use  of  LMWH  was  associated  with  a  signiﬁcant  reduction
in  major  bleeding  or  transfusion  compared  with  UFH,  as  in
the  meta-analysis  of  Silvain  et  al.,  in  which  a  20%  relative
risk  reduction  was  observed  [9].  No  difference  was  observed
in  terms  of  bleeding  complications  according  to  the  type  of
AMI  in  our  study.
Figure 4. Three-year myocardial infarction and stroke-free
survival (propensity score-matched groups). Log-rank: 2 = 4.67,
P = 0.031. LMWH: low-molecular-weight heparin; UFH: unfraction-
ated heparin.
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Current  updated  guidelines  for  anticoagulation  in
atients  requiring  PCI  for  STEMI  or  NSTEMI  with  a  medium-
o-very  high-risk  of  ischaemia  produced  by  the  American
ollege  of  Cardiology,  American  Heart  Association  and  Soci-
ty  of  Cardiac  Angiography  and  Intervention,  as  well  as
uidelines  from  the  Task  Force  on  Myocardial  Revascular-
zation  of  the  European  Society  of  Cardiology,  consider  UFH
s  a  class  1  recommendation  for  this  indication,  despite
imited  supporting  evidence  (level  of  evidence  C)  [14,23].
owever,  our  study,  as  well  as  current  available  data  and
harmacological  properties,  suggest  that  LMWH,  especially
noxaparin,  could  be  an  attractive  strategy  in  the  manage-
ent  of  patients  with  AMI.
tudy limitations
ur  study  has  the  same  limitation  as  all  observational  studies
namely,  no  causality  can  be  asserted  between  varia-
les  that  are  correlated.  Comparisons  between  patients
eceiving  LMWH  and  those  receiving  UFH  were  not  random-
zed  and,  despite  careful  adjustments  for  a  large  number
f  potentially  confounding  variables,  the  results  can  only
e  considered  as  indicative.  The  use  of  propensity  score-
djusted  cohorts,  however,  limits  the  biases  inherent  to
bservational  data,  by  giving  the  opportunity  to  compare
utcomes  in  cohorts  of  patients  with  similar  baseline  char-
cteristics;  this  strengthens  our  ﬁndings  considerably.  One
f  the  major  limitations  of  this  study  is  that  the  doses
f  LMWH  and  UFH  used  were  not  recorded  in  this  reg-
stry.  However,  it  is  noteworthy  that  most  centres  used
uropean  Society  of  Cardiology  guidelines  (1  mg/kg  subcu-
aneously  twice  daily)  or  dose-adjustment  protocols  that
onform  to  the  EXTRACT-TIMI  25  regimen  for  elderly  patients
0.75  mg/kg  subcutaneously  twice  daily)  [3,24]. Finally,  we
id  not  distinguish  between  patients  receiving  enoxaparin  or
ther  LMWHs,  as  96%  of  the  patients  on  LMWH  (1846/1932)
eceived  enoxaparin.
onclusion
ur  data  show  that  the  use  of  LMWH  in  real-world  clini-
al  practice  is  associated  with  less  bleeding  and  a  better
-year  survival  rate  in  patients  with  AMI.  These  ﬁndings,
hich  were  conﬁrmed  in  propensity  score-matched  popu-
ations  with  similar  baseline  characteristics,  suggest  that
MWH  could  replace  UFH  in  these  high-risk  patients  as  the
ntithrombotic  agent  of  choice  in  the  management  of  ACS.
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